Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:CGEN NASDAQ:DMAC NASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.28$1.22$1.05▼$10.16$40.00M1.64270,981 shs20,127 shsCGENCompugen$1.60+0.9%$1.58$1.13▼$2.66$141.09M2.57361,360 shs18,024 shsDMACDiaMedica Therapeutics$4.24-1.5%$3.91$3.19▼$6.82$181.87M1.17103,303 shs17,401 shsNVCTNuvectis Pharma$8.34+0.7%$8.67$4.44▼$11.80$173.28M-0.25133,720 shs3,991 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-3.76%-2.29%+6.67%-30.81%-82.86%CGENCompugen-0.63%-7.06%-3.66%+8.97%-17.28%DMACDiaMedica Therapeutics+7.23%+17.81%+17.81%+23.92%+20.11%NVCTNuvectis Pharma+0.73%+9.23%-1.55%-4.83%+24.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics3.7354 of 5 stars3.55.00.00.03.82.50.6CGENCompugen1.6068 of 5 stars3.52.00.00.02.70.00.0DMACDiaMedica Therapeutics1.1684 of 5 stars3.50.00.00.02.70.00.0NVCTNuvectis Pharma3.3043 of 5 stars3.50.00.00.04.45.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$17.711,283.93% UpsideCGENCompugen 3.00Buy$4.00150.78% UpsideDMACDiaMedica Therapeutics 3.00Buy$8.0088.81% UpsideNVCTNuvectis Pharma 3.00Buy$17.00103.89% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, DMAC, NVCT, and CGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/16/2025ACRVAcrivon TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/5/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.005/4/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACGENCompugen$27.86M5.11N/AN/A$0.62 per share2.57DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)CGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)Latest ACRV, DMAC, NVCT, and CGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ACRVAcrivon Therapeutics-$0.57N/AN/AN/AN/AN/A8/6/2025Q2 2025DMACDiaMedica Therapeutics-$0.18N/AN/AN/AN/AN/A8/5/2025Q2 2025CGENCompugen-$0.07N/AN/AN/A$3.95 millionN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25N/AN/AN/AN/AN/A5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57-$0.51+$0.06-$0.51N/AN/A5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A11.1711.17CGENCompugenN/A5.095.09DMACDiaMedica TherapeuticsN/A8.028.02NVCTNuvectis PharmaN/A3.283.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%CGENCompugen12.22%DMACDiaMedica Therapeutics10.12%NVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%CGENCompugen9.50%DMACDiaMedica Therapeutics7.30%NVCTNuvectis Pharma30.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.35 million28.69 millionNot OptionableCGENCompugen7089.24 million80.76 millionOptionableDMACDiaMedica Therapeutics2042.88 million39.75 millionOptionableNVCTNuvectis Pharma820.89 million14.52 millionNot OptionableACRV, DMAC, NVCT, and CGEN HeadlinesRecent News About These CompaniesAustin Wealth Management LLC Buys Shares of 40,250 Nuvectis Pharma, Inc. (NASDAQ:NVCT)July 11, 2025 | marketbeat.comIridian Asset Management LLC CT Acquires Shares of 253,972 Nuvectis Pharma, Inc. (NASDAQ:NVCT)July 9, 2025 | marketbeat.comNuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading TherapiesJuly 8, 2025 | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Lowered to "Sell" Rating by Wall Street ZenJune 29, 2025 | marketbeat.comMarlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 25, 2025 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Buys $44,767.97 in StockJune 24, 2025 | marketbeat.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 5,399 Shares of StockJune 21, 2025 | insidertrades.comNuvectis Pharma (NASDAQ:NVCT) Stock Rating Upgraded by Wall Street ZenJune 21, 2025 | marketbeat.comMarlio Charles Mosseri Purchases 5,399 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 20, 2025 | marketbeat.comMarlio Charles Mosseri Purchases 28,043 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 20, 2025 | marketbeat.comInsiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchasesJune 18, 2025 | finance.yahoo.comNuvectis Pharma: Still Interesting, But Still Too Risky To Jump InJune 18, 2025 | seekingalpha.comNuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 16, 2025 | globenewswire.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 SharesMay 14, 2025 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases 2,650 Shares of StockMay 10, 2025 | insidertrades.comDoes Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?May 9, 2025 | zacks.comNuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth PlansMay 9, 2025 | finance.yahoo.comNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | ...May 6, 2025 | gurufocus.comNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comNuvectis Pharma, Inc. Reports Promising Phase 1a Data for NXP900 and Secures $15.5 Million FinancingMay 6, 2025 | quiverquant.comQNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRV, DMAC, NVCT, and CGEN Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.28 0.00 (0.00%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Compugen NASDAQ:CGEN$1.60 +0.02 (+0.95%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.DiaMedica Therapeutics NASDAQ:DMAC$4.24 -0.06 (-1.47%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Nuvectis Pharma NASDAQ:NVCT$8.34 +0.06 (+0.70%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
